Nick Leschly at JPM20 (Jeff Rumans)
Updated: 2seventy lays off 40% of staff, prunes CAR-T pipeline as Nick Leschly steps down as CEO
With an early-stage CAR-T under clinical hold, 2seventy bio is slashing its headcount by 40% and capping spending on some pipeline …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
